It has been a major week in the stem cell industry, with partnerships, licensing deals, and pre-clinical findings recently announced. Check out the latest coverage below. [Read more…]
BrainXell Inc. (Madison, Wisconsin) and iPS Academia Japan, Inc. (Kyoto, Japan) have announced a global licensing agreement covering some of iPS Academia Japan’s induced pluripotent stem (iPS) cell patent portfolio. BrainXell may now develop and commercialize iPS-derived cells and offer related services to its customers under this non-exclusive agreement. Learn more below.